Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F020 - Approaching Severe Inflammatory Skin Disease in Children

Friday, February 16; 1:00 PM - 3:00 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify the psychosocial implications of severe skin disease on patients and families.
  • Discuss the innovations in new drug development for children with severe atopic dermatitis.
  • Recognize the impact of paradigm shifting new drugs in pediatric dermatology.

Description

Care of children with skin disease often includes addressing family distress that can interfere with parent-provider communication. An experienced clinician will offer perspective about personal medical challenges to provide lessons in empathy. Protecting children from perceived risks excluded them from participating in clinical trials of groundbreaking drugs until a shift in policy helped recognize the importance of including them. Efforts to ensure safe and effective new pediatric treatments will be summarized, with recommendations for off-label treatment pending better data. Experienced clinicians will provide their perspectives on the impact of new drugs, including initial promise, long-term efficacy and unforeseen complications.

Disclosures

  • Antaya, Richard J., MD: Astellas Pharma US, Inc – I(S); Ferndale Laboratories, Inc. – C(Fees); Hoffman-La Roche Ltd. – C(Fees); LAM Pharma – I(Fees); Pfizer Inc. – A(H); Promius Pharma, LLC – A(H);
  • Friedlander, Sheila Fallon, MD: Menlo Therapeutics – A(H); Pfizer Inc. – A(H);
  • Lucky, Anne W., MD: Castle Creek Pharmaceuticals – I(NC); Fibrocell Science – C(Fees); ProQR – C(H);
  • Siegfried, Elaine C., MD: Allergan, Inc – I(Fees); Amgen – I(OB); Dermavant Sciences – C(Fees); Eli Lilly and Company – I(Fees); GlaxoSmithKline – Data Safety Monitoring Board(Fees); Janssen Pharmaceuticals, Inc – I(Fees); Mayne Pharma Group – I(Fees); Medimetriks Pharmaceuticals, Inc. – Data Safety Monitoring Board(Fees); Novan – C(Fees); Pfizer Inc. – A(Fees); Pierre Fabre Dermo-Cosmétique US – I(Fees); Regeneron – I(Fees); Valeant Pharmaceuticals North America LLC – C(Fees); Verrica Pharmaceuticals Inc – A(Fees);
Schedule
Friday, February 16
1:00 PM
Dr. Siegfried / Introduction
1:05 PM
Dr. Antaya / Lessons from the Other Side of the Exam Table
1:35 PM
Dr. Siegfried / New Drug Development in Children
2:00 PM
Dr. Siegfried / A Perspective on the Impact of Groundbreaking Drugs
2:05 PM
Dr. Lucky / A Perspective on the Impact of Groundbreaking Drugs-Isotretinoin for Acne
2:20 PM
Dr. Friedlander / A Perspective on the Impact of Groundbreaking Drugs-Propranolol for Hemangioma of Infancy
2:35 PM
Dr. Siegfried / A Perspective on the Impact of Groundbreaking Drugs-TCIs and Dupilumab for Eczema
2:50 PM
All faculty / Q and A
Event Details
  • Date
    Friday, February 16
  • Time
    1:00 PM - 3:00 PM
  • Location
    Ballroom 20A
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Elaine C. Siegfried, MD, FAAD
Speakers
  • Anne W. Lucky, MD, FAAD
  • Richard J. Antaya, MD, FAAD
  • Sheila Fallon Friedlander, MD, FAAD